ARVINAS, INC. Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount
ARVINAS, INC. (ARVN) had Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount of $22.65 million as of 2020-12-31, per its 10-K filed 2021-03-01.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions · last filed 2021-03-01
- 2020-12-31: Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount $22.65M.
| Period end | Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount |
|---|---|
| 2020-12-31 | $22.65M 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |